Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK923295 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| GSK923295 | EXPERIMENTAL | anti-mitotic compound under study |
| Name | Type | Description |
|---|---|---|
| GSK923295 | DRUG | anti-mitotic compound |
Inclusion Criteria: * Signed, written informed consent provided. * a) Stage 1 Subjects: Histologically or cytologically confirmed diagnosis of solid tumor malignancy that is not responsive to accepted standard therapies, or for which there is no standard therapy. b) Stage 2 Subjects: Histologica...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
GSK923295 is an investigational small molecule being developed for the treatment of cancer. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and effectiveness in patients.
GSK923295 is being developed by GSK plc, a global pharmaceutical company. GSK plc is publicly traded on the London Stock Exchange under the ticker symbol GSK.
GSK923295 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety, pharmacokinetics, and pharmacodynamics in patients with cancer.
GSK923295 has been studied in one completed Phase 1 clinical trial with the identifier NCT00504790. This trial assessed the safety, pharmacokinetics, and pharmacodynamics of GSK923295 in subjects with refractory cancer. The trial enrolled 39 participants in the United States.
GSK923295 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed Phase 1 trial (NCT00504790) evaluated its safety and other characteristics, but it has not yet received regulatory approval for any use.